华海药业：获得富马酸喹硫平缓释片药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Extended-Release Tablets, which are used to treat schizophrenia and depressive episodes of bipolar disorder [1] Summary by Relevant Categories Product Approval - The approved drug was originally developed by AstraZeneca and was launched in the United States in 2007 [1] - The approval of this drug enhances the company's product line and improves its market competitiveness [1] Market Potential - According to data from Minet, the projected domestic market sales for this drug are approximately 451 million yuan in 2024 [1] R&D Investment - The company has invested approximately 16.93 million yuan in the research and development of this project [1]